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Retrospective analysis of clinical yeast isolates in a hospital
in the centre of Portugal: spectrum and revision of the
identification procedures
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We conducted a four-year (20032006) retrospective study of yeasts recovered in a
hospital laboratory in the centre of Portugal to evaluate the epidemiology of yeast
infections. Clinical isolates and data were gathered from 751 patients correspond-
ing to 906 episodes of yeast infection. The isolates were first identified using
classical and commercial methods, routinely employed at the hospital laboratory.
We then re-identified the same isolates using RFLP of the ITS 5.8S rRNA gene and
sequence of the D1/D2 domain of the 26S rRNA gene. Candida parapsilosis isolates
were re-identified using the Ban I digestion of the SADH gene. C. albicans was the
most frequently isolated of the yeasts found in the analysed specimens, with an
overall incidence of 69.6% and then in deceasing order, C. glabrata, C. tropicalis, C.
parapsilosis and C. krusei. C. parapsilosis was most frequently recovered from
younger patients, decreasing with age, while C. glabrata occurrence increased with
age. We found an increased number of cases of fungemia per 100,000 people per
year, reaching a maximum of 4.4 during 2006.
Keywords Yeast infections, molecular yeast identification, risk factor, Candida
metapsilosis, Candida orthopsilosis
Introduction
Yeasts are ubiquitous in the environment and are also
part of the normal flora of the human body. Many
yeasts, particularly members of the genus Candida, are
opportunistic pathogens causing infections in indivi-
duals with immune diseases or with a weakened
immune system. Bloodstream infections involving
Candida spp. can be considered as emerging infections.
The origin of the yeast infection can either be
endogenous or exogenous and several studies point to
either possibility [15]. Hedderwick and co-workers [6]
carried out a 6-month surveillance of yeast coloniza-
tion and infections in an adult intensive care unit, and
found a low degree of cross-transmission for Candida
albicans, but none for the other Candida species
included in the investigation. Irrespective of this, the
incidence of fungal infections has increased in the last
three decades [710]. This increase may be the result of
the greater the number of patients with dysfunctional
immune systems [11] due to iatrogenic factors. In
particular, the yeasts of the genus Candida are con-
sidered as the most common fungal agents of nosoco-
mial invasive fungal infections, with an average
mortality rate of 30% [10,12,13]. In recent years, the
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list of Candida species known as human pathogens has
become more diverse, although the epidemiology of
yeast infections is still ill-defined. C. albicans is
the most frequent cause of candidemia, but C. glabrata,
C. parapsilosis, C. krusei, C. lusitaniae and C. tropicalis
have emerged as agents of human infections [9,10].
Moreover, these species have different susceptibility
patterns toward antifungals [14]. Recent guidelines for
the treatment of candidiosis point out that only
through an accurate diagnosis of the etiologic agents
can efficient therapy be designed [10,15,16].
The diagnosis of a yeast infection depends on fast
and reliable identification methods of causative agents.
Classical methods involving phenotypical analyses and
serological tests [17] are time consuming and cause
delays in the diagnoses and hamper the rapid choice of
appropriate therapy. There has been an increasing
interest in the application of molecular identification
techniques because they are faster and more accurate
[18], although they are more expensive and require
advanced training for personnel.
The objective of this study was to characterize the
occurence of yeast infections in a population in the
centre of Portugal, attending a Hospital that serves a
total population of 2,500,000 people. The accuracy of
the more classic methods of yeast identification em-
ployed in the clinical centre was evaluated by the re-
identification of the yeast isolates using two different
molecular biology techniques (RFLP of the ITS 5.8S
rRNA gene and sequencing of the domain D1/D2 of
the 26S rRNA gene). A bank of clinical isolates was
constructed, together with a retrospective study of the
clinical data regarding the patients from whom the
yeasts were isolated.
Materials and methods
This is a retrospective study including data from 2003
to 2006 concerning yeasts recovered as etiologic agents
of human infections at the Centro Hospitalar de
Coimbra (CHC). The hospital has a target population
of 500,000 people (General Hospital and Maternity)
and two million for the Paediatric Hospital.
Clinical data
Retrospectively, relevant clinical information of pa-
tients diagnosed with yeast infections obtained from the
database of the Clinical Pathology Department of the
CHC, were gathered and added to a data bank. The
following risk factors/underlying diseases were consid-
ered; cystic fibrosis, immunodepression, cancer, dia-
betes, AIDS, catheter, post-operation status, pregnancy,
antibiotic treatment, persistent fever (meaning persis-
tent fever of unknown origin), solid organ transplant,
admission in the reanimation unit, haemodialysis and
burns. For every episode, the following data was
recorded; age, gender, in- or outpatient status, yeast
identification, collection date and specimen from which
the yeast was isolated.
Standard identification procedure for yeasts isolated in the
hospital laboratory
The methodology used in the microbiology laboratory
of the Clinical Pathology Department of the CHC
starts with a direct microscopic examination of a smear
of the specimen. This is followed by inoculating a
portion of the specimen onto Sabouraud medium or
blood culture bottle (BACTEC 9240 System with
Aerobic Plus or F blood culture bottles (Becton
Dickinson, The Netherlands). When the presence of
yeast colonies was suspected, a rapid identification
procedure was performed using the Bichro Latex
albicans Fumouze (Fumouze Diagnostics, France),
with a positive result indicating the identification of
C. albicans. Alternatively, if the test result was negative,
the Api† ID32C (bioMe´rieux, Portugal) was used in
identifying the isolate.
Re-identification of yeasts by molecular biology methods
The yeast isolates were re-identified using RFLP of the
5.8S rRNA gene and of the adjacent ITS1 and ITS2,
and by sequencing the D1/D2 contiguous fragments of
the 26S rDNA. Total genomic DNA was extracted
using the isopropanol method and specific gene ampli-
fication was obtained using the primers in Table 1. The
identification by RFLP of the 5.8S and ITS1 and ITS2
region of the 18S rDNA was carried out as described
previously [1921]. Reference strains of C. dubliniensis
and C. lusitaniae were obtained and, using the meth-
odology described above, we determined the restriction
patterns of these species (results not shown). The
sequencing of the D1/D2 contiguous fragments of the
Table 1 Primers used in this study.
Primer name Sequence Reference
NL-1 5?- GCA TAT CAA TAA GCG GAG
GAA AAG -3?
[26]
NL-4 5?- GGT CCG TGT TTC AAG ACG G -3?
ITS-1 5?-TCC GTA GGT GAA CCT GCG G- 3? [27]
ITS-2 5?-TCC TCC GCT TAT TGA TAT GC-3?
S1F 5?- GTT GAT GCT GTT GGA TTG T-3? [25]
SIR 5?- CAA TGC CAA ATC TCC CAA -3?
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26S rDNA was performed according to Kurtzman and
Robnett [22], and assumed as the reference method.
The sequences obtained were used to identify the yeasts
by BLAST-search (GenBank; www.ncbi.nlm.nih.gov).
Using Tavanti and co-workers methods [23], the re-
identification of the clinical isolates of Candida para-
psilosis was performed by RFLP of the SADH gene.
This method is based on the restriction of the SADH
(‘Secondary Alcohol Dehydrogenase’) gene by the Ban
I enzyme. This re-identification was performed on 50
different clinical isolates identified as Candida para-
psilosis collected during this study.
Statistics
Descriptive statistics was used to summarize the data.
Risk factors significantly associated with bloodstream
infections in the univariate analysis that occurred in
5% of patients were evaluated in a stepwise logistic
regression model.
Results
Demographic characteristics and risk factors
The total number of yeast infections diagnosed during
the period in study was 906, although this number does
not correspond to the number of patients since 155
suffered from repeat episodes. The total number of
patients with at least one yeast infection was 751. The
distribution of patients in age groups (Table 2) showed
that the number of cases increased with age. During the
4-year period, there was a considerable increase in the
number of cases diagnosed at the hospital laboratory
each year. As for the gender, 52.3% of episodes
occurred in men, and 47.7% in women (Table 2).
This study aimed at analyzing the spectrum of yeast
infections and all the yeast isolates to which an
aetiological role was attributed, independently of the
place/tissue of infections. Consequently, they were
recovered from different biological products (Table 2).
Respiratory and urinary tract specimens were the most
frequent source of yeasts. The number of blood isolates,
corresponding to bloodstream infections (BSI) was 36,
and the number of catheters from which yeasts were
recovered was 60.
The clinical data of the patients from whom the
isolates were obtained, either as in- or outpatients, was
analyzed according to the underlying diseases and/or
predisposing conditions, with the purpose of identify-
ing the most important risk factors. A high number of
episodes (248) did not have any associated risk factors.
The highest numbers of episodes were associated with
prolonged antibiotic treatment and persistent fever
(Table 2).
Re-identification of the clinical isolates by molecular biology
Our results showed that the methodology used by the
microbiology laboratory of the Clinical Pathology
Department of the CHC was very accurate and reliable,
since only two isolates were misidentified when results
were compared to those with the two different mole-
cular techniques. One isolate, obtained from a urine
Table 2 Characteristics of the patients’ data and of the samples from
which yeast isolates were obtained.
Data
Number of
patients (%)
Number of
episodes (%)
Year of study
2003 139 153
2004 131 146
2005 197 237
2006 308 370
Sex
Male 387 (51.5)
Female 364 (48.5)
Age groups (years) (n754)
50.5 28 (3.7) 38 (4.2)
0.53 49 (6.5) 60 (6.6)
316 63 (8.4) 75 (8.3)
1640 113 (15.0) 129 (14.2)
4065 116 (15.4) 159 (17.5)
]65 385 (51.1) 445 (49.1)
Risk factor/underlying disease (n1467)
Antibiotics 560 (38.2)
Burns 1 (0.1)
Cancer 28 (1.9)
Catheter 131 (8.9)
Cystic fibrosis 5 (0.3)
Diabetes 19 (1.3)
Fever 457 (31.2)
Haemodialysis 3 (0.2)
HIV/AIDS 48 (3.3)
Immunodepression 30 (2.0)
Pregnancy 24 (1.6)
Post surgery 64 (4.4)
Reanimation unit 82 (5.6)
Solid organ transplant 15 (1.0)
Specimens (n906)
Respiratory 317 (35.0)
Urine 260 (28.7)
Catheter 60 (6.6)
Blood 36 (4.0)
Faeces 46 (5.1)
Vaginal 50 (5.5)
Skin 31 (3.4)
Other* 104 (11.5)
*Other specimens: gastric fluid (5), peritoneal fluid (28), male
urethral fluid (4), cerebrospinal fluid (11), bile (14), unspecified tissue
(2), unspecified fluid/pus (59), exsudate of the pharynx/tongue (20).
– 2009 ISHAM, Medical Mycology
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sample was first identified with the hospital routine
procedures as C. guilliermondii and re-identified as
C. albicans using the RFLP method. Surprisingly, when
the D1/D2 domain of the 26S rDNA was sequenced,
this same isolate was re-identified as C. tropicalis. Since
we assumed this last procedure as the reference
method, we decided to accept the last identification.
Another isolate, first identified by classic methods as
C. intermedia was re-identified by sequencing of the
D1/D2 domains of the 26S gene as C. tropicalis.
Re-identification of C. parapsilosis isolates
The redefinition of the taxonomic group to which C.
parapsilosis includes two additional species, C. orthop-
silosis and C. metapsilosis [23], we reidentified the 50
clinical isolates indicated to be C. parapsilosis. All the
C. parapsilosis isolates had been identified by classic
methods, by RFLP of the ITS 5.8S rDNA and
sequencing of the D1/D2 domains of the 26S gene.
For the re-identification, we used the restriction
pattern of the SADH gene with the Ban I enzyme
[23]. Of the 50 isolates identified as C. parapsilosis, to
which clinical pathologists originally attributed aetio-
logical significance, five were re-identified as C.
metapsilosis and six as C. orthopsilosis. The restriction
patterns of some of the re-identified isolates are
depicted in Fig. 1, along with the restriction pattern
of C. parapsilosis.
In the group of yeasts re-identified as C. orthopsi-
losis, one was isolated from peritoneal fluid of a 25-day-
old infant with an intestinal perforation admitted in the
intensive care unit (ICU). One month later, C. orthop-
silosis was again recovered from the blood of the same
patient. At the time of blood collection and when
admitted to the ICU, the patient was being medicated
with antibiotics. A third isolate of the same species was
obtained from a catheter in the same boy. Among the
isolates re-identified as C. metapsilosis, a particular
isolate was more thoroughly investigated since it had
been recovered from peritoneal fluid of a liver trans-
plant patient, who received three liver transplants. The
first isolate was recovered from a drainage catheter
after the third transplant. It was identified by the
microbiology laboratory as C. parapsilosis. The same
yeast was also obtained from peritoneal fluid and from
a urinary catheter. A histopathological analysis of a
liver biopsy, also from that period, revealed yeast cells.
Spectrum of agents
The five species most often recovered were, in decreas-
ing order, C. albicans, C. glabrata, C. tropicalis, C.
parapsilosis and C. krusei (Table 3). C. albicans
accounted for 69.6% of the total number of yeast
infections while non-C. albicans Candida species ac-
counted for 28.3% of the yeast infections (Table 3). A
total of 8 isolates of Saccharomyces cerevisiae were
obtained. In regard to Cryptococcus neoformans, be-
sides the systemic isolates, two were obtained from skin
lesions (Table 3). From the analysis of the incidence of
non-C. albicans Candida species in different age groups
(Fig. 2), we conclude that C. parapsilosis is the
predominant species in patients up to 16 years, whereas
C. glabrata is more common in patients older than 16
years of age. Starting at the age group from 16 to 40
years, the relative incidence of C. glabrata increased
progressively, whereas C. parapsilosis followed the
opposite tendency.
Blood stream infections (BSI)
The number of blood cultures positive for yeasts
obtained during the period considered in this study
was 89. However, there were 2,153 blood cultures
performed to detect fungi due to clinical indicators of
infection. Of the total number of tests performed, only
24 (1.1%) yielded positive results using blood culture
bottles. The other yeasts involved in candidemia, were
isolated from patients with no clinical evidence of BSI,
but with clinical evidence of a bacteremia, from which
the blood cultures were found to be positive for yeasts.
Fig. 1 Re-identification of clinical isolates of Candida parapsilosis by RFLP of the SADH gene by the enzyme BanI. The resulting fragments
were separated by electrophoresis in a 1% agarose gel. Legend: Lane 11  C. metapsilosis; Lanes 4, 8, 14  C. orthopsilosis; Lanes 2, 3, 5, 6, 7, 9,
10, 12, 13, 15, 16, 17  C. parapsilosis; Lanes 1, 18  Molecular weight marker.
– 2009 ISHAM, Medical Mycology
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The low number of positive blood culture tests led us to
estimate the number of episodes of candidemia per
100,000 people per year, between 2003 and 2006. For
this calculation, only the data of patients older than 16
years were taken into account. We considered that this
hospital has an catchment area of 500,000 people.
From the total yeast isolates from the blood, and due to
the retrospective nature of this study, we could only
obtain patient’s data from 36 cases. Of the total
episodes of candidemia considered, about 95% were
detected in in-patients. Candida albicans was the most
frequent yeast species (61.1%) followed by C. para-
Table 3 Yeast species isolated from different specimens
Specimen
Respiratory* Urine Catheter Blood Faeces Vaginal Skin Other Total number (%)
C. albicans 235 177 36 22 31 42 23 65 631 (69.6)
C. catenulata 0 1 0 0 0 1 0 0 2 (0.2)
C. glabrata 24 25 1 1 5 6 1 6 69 (7.6)
C. guilliermondii 3 2 2 0 1 0 0 7 15 (1.7)
C. inconspicua 2 0 0 0 0 0 0 0 2 (0.2)
C. intermedia 2 2 1 0 0 0 0 2 7 (0.8)
C. krusei 6 8 3 0 3 0 0 3 23 (2.5)
C. lusitaniae 3 3 0 0 0 0 0 1 7 (0.8)
C. membranaefaciens 0 0 1 0 0 0 0 0 1 (0.1)
C. metapsilosis 1 0 0 0 0 0 0 1 2 (0.2)
C. orthopsilosis 1 0 1 1 0 0 0 1 4 (0.4)
C. parapsilosis 8 7 14 8 2 0 4 7 50 (5.5)
C. pelliculosa 0 0 0 1 0 0 0 0 1 (0.1)
C. pulcherrima 1 0 0 0 0 0 0 0 1 (0.1)
C. rugosa 1 0 0 0 0 0 0 0 1 (0.1)
C. sake 1 1 0 0 0 0 0 0 2 (0.2)
C. tropicalis 28 33 0 0 0 0 1 5 67 (7.4)
C. utilis 0 0 1 0 0 0 0 1 2 (0.2)
Cryptococcus neoformans 0 0 0 3 0 0 0 3 6 (0.7)
Saccharomyces cerevisiae 1 1 0 0 4 1 1 0 8 (0.9)
Other 3 0 0 0 0 0 0 2 5 (0.6)
Total (%) 320 (35.3) 260(28.7) (27.2) 60 (6.6) 36 (4.0) 46 (5.1) 50 (5.5) 30 (3.3) 104 (11.5) 906
*It includes bronchoalveolar lavage liquids, nasopharyngeal aspirates and expectorated suptum.
Fig. 2 Distribution of the most common non-Candida albicans Candida species per age group.
– 2009 ISHAM, Medical Mycology
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psilosis (22.2%), Cryptococcus neoformans (8.3%). One
of the isolates first identified as C. parapsilosis, was re-
identified as C. orthopsilosis. It is noteworthy that there
was an absence of C. tropicalis and C. krusei, which are
frequently found as pathogens in other sites such as the
respiratory and urinary tracts. The results showed four
episodes of C. krusei associated with catheters, but
none in blood culture. A statistical study was per-
formed in order to assess the probability of a patient
developing a blood stream yeast infection. The results
showed that the only variables with statistic impact was
the presence of HIV (OR2.962; P0.035) or hae-
modialysis (OR12.411; P0.050). This last para-
meter shows a higher odds ratio when it is associated
with patients who are over 65 years (OR16.920; P
0.048). In addition, patients in which the clinician
described persistent fevers of unknown origin have
higher probability of a BSI (OR4.05; P0.001).
Discussion
The main goal of this study was to understand the
incidence of yeast infections in a population in
the centre of Portugal and to assess the accuracy of
the identification procedures used. It was also our aim
to identify groups of patients at higher risk of acquiring
a BSI.
The main risk factors contributing to yeast infections
and their classification in order of importance have
been the subject of several studies [10,24]. Suggestions
have been made of the usefulness of assessing the need
for early therapy or even prophylaxis against fungal
infections, now that the most important risk factors are
known [10] such as catheterized patients [25], those
receiving prolonged antibiotic treatment [26], preg-
nancy [27], patients with uncontrolled diabetes [28],
solid organ transplant recipients [29], patients with
AIDS [30] and cancer patients undergoing cytotoxic
chemotherapy [29]. In the population here studied, the
majority of yeast infections occurred in patients with all
of these risk factors.
Age is also a critical factor and was considered in our
study. As expected, the age group where the most yeast
infections were diagnosed was in patients over 65 years.
The latter tend to present signs of immunosenescence, a
gradual reduction of the effectiveness of the immune
system due to the natural ageing process [31]. Addi-
tionally, the ageing of the mucosa and the skin weakens
nonspecific defences against invading microorganisms
[32]. Also, the patients in this age group have increased
probability of suffering from diseases which are risk
factors for yeast infections, such as diabetes, renal
insufficiency (haemodialysis) and cancer (chemother-
apy) [26,29,33,34]. Accordingly, the data we obtained
showed that patients older than 65 years under
haemodialysis had the highest risk of developing a BSI.
The observation that a high number of episodes was
not associated with a risk factor clearly indicates that
either the clinical data of the clinical pathology
database are not complete and/or there are clinical
features that clinicians do not identify as being related
to fungal infections. However, it is important to note
that the data was collected from the database of the
Clinical Pathology Department of the CHC and not
from the complete clinical file of the patients. It is likely
that the transfer of clinical information between the
assisting physician and the clinical pathologist might be
incomplete. The retrospective nature of the study,
coupled to the exiguous data transfer to the clinical
pathologist, hypothetically led to the omission of
important risk factors. This limitation has been de-
scribed in other epidemiological studies based in
hospital laboratories and the clinical data associated
with it [35].
One of the most serious yeast infections is that of the
bloodstream, which is associated with a high mortality
[10]. In addition to the increased frequency of this type
of infection, there is also a tendency for the emergence
of new pathogenic species. A study recently published
in the Portuguese population showed that the incidence
of fungemia is 2.7 per 1,000 hospital admissions with a
mortality rate of 39.3% [12].
The diagnosis of fungemia is sometimes hindered by
the methods used to establish it. Blood culture methods
may often yield false negative results at an early stage of
infection [36]. According to Pfaller and Diekema [10],
the frequency with which blood culture tests are
requested and the type of culture employed can affect
the fungemia incidence rates in epidemiological studies
based on laboratory results. A study concerning the
efficiency of the BACTEC 9240, the blood culture
bottle used in the investigation, showed that it only
spiked with 100 CFU/ml of different yeasts. Therefore,
about 10% of the aerobic culture bottles gave false
negative results after a 21-day incubation. Further-
more, the percentage of false negatives increased when
the incubation time was reduced to 5 days [37].
Considering that in many cases of bloodstream infec-
tion the concentration of yeast cells can be less than 10
CFU/ml [38], we can infer that the clinical practice,
using a 5-day incubation period, may be expected to
yield an even larger percentage of false negative results.
The number of candidemia episodes obtained during
this study is close to the incidence found in other
European countries like Norway (2 and 3 per 100,000
inhabitants) and Spain (4.9 per 100,000 inhabitants).
– 2009 ISHAM, Medical Mycology
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However, the incidence of candidemia in this investiga-
tion is considerably lower than that found in North
American studies (between 6 and 24 cases per 100,000
inhabitants, per year) [10]. A study recently published
showed that in Scotland the incidence of candidemia is
4.8 cases per 100,000 population per year [35]. Never-
theless, we believe that the number of laboratory
diagnosed bloodstream infections is certainly below
the real incidence. In many cases in which there was a
strong clinical suspicion of a fungal infection, anti-
fungal medication was administered with a positive
outcome even when the blood culture test turned
negative. A reliable, highly efficient method for detect-
ing yeast blood infections is required.
Although this study included a wide range of clinical
isolates, from skin to systemic candidiosis, we believe
that at the clinical setting level, it is more important to
recognize the probability of a patient to develop a
systemic yeast infection, than a localized yeast infec-
tion. Others have pointed that this is especially true if
certain risk factors are present, for example if gastro-
intestinal pathologies are present [12,35].
A conclusion drawn from this study is that the
combination of methods used in the microbiology
laboratory of the clinical pathology service of CHC
are excellent since only two yeast isolates were re-
identified by molecular biology as different species. We
did not consider for this calculation the re-identifica-
tion of the isolates of C. parapsilosis, since C. metapsi-
losis and C. orthopsilosis are new species that did not
yet exist in the databases of the clinical routine
identification methods. The combination of several
methods certainly contributes to the quality and
efficacy of the identification procedure routinely used
at the hospital laboratory.
In recent years there has been a growing interest in
using and developing new identification methods based
on molecular biology, like real-time PCR [39], sequen-
cing and/or RFLP of different regions of the genome
[18,21,40,41]. These techniques take advantage of
regions of the genome, which, in addition to being
conserved in all yeast species, have a great interspecies
variability. These methods provide more reliable results
in a shorter period of time. However, the cost of the
equipment and need for highly trained staff may be
disadvantages to their use.
A characterization of yeast infections requires the
analysis of the isolated species. Although most epide-
miological studies in the literature concern BSI,
C. albicans would be expected to be the most frequently
isolated yeast. In spite of that, it is noteworthy that we
found a great variety of non-C. albicans Candida
species. In the literature, there are several reports
indicating the tendency for diversification of species
of yeast pathogenic to humans [10,42]. This can be due
to the increased number of individuals with greater
susceptibility to this kind of infectious agents, as well as
to the selection of several species due to differences in
their intrinsic susceptibilities to some of the most
frequently employed antifungals [10,43]. The distribu-
tion of infections within the age group of this study was
similar to those obtained in an investigation in the
USA concerning systemic infections [10]. Studies con-
ducted in neonatal ICUs concluded that neonates
became colonized by C. parapsilosis acquired from
the ICU setting and not from their mothers [4446].
This yeast species was also the most commonly isolated
from the hands of healthcare workers, due to the ability
of higher persistence on the hands [47]. However, no
link was found between this and patient acquisition of
the infection/colonization [6].
Saccharomyces cerevisiae is an uncommon pathogen.
Disease caused by this ‘friendly’ yeast is associated with
severe immunosuppressed patients [48]. During the
four-year period of this study, none of the eight isolates
were recovered from immunocompetent patients. In the
majority of circumstances the patients were very
debilitated or immunodepressed.
C. dubliniensis is usually associated with HIV-positive
patients although some cases have been reported in
other patient populations [49]. C. dubliniensis may be
easily misidentified as C. albicans due to their close
phenotypic resemblance [50]. The re-identification of
C. albicans isolates by sequencing of the D1/D2
domains of the 26S rRNA gene confirmed that in the
period considered in this study no C. dubliniensis
strains were isolated. In a one-year prevalence study
in a Dutch hospital, 0.8% of the germ tube positive
yeasts were C. dubliniensis [49]. An American study
mentioned an incidence of 0.9% for this species [51],
with most isolates recovered from oropharyngeal and
fecal samples. Given these previous reports of low
incidence, and considering that our investigation did
not include oropharyngeal specimens and only includes
a total of 38 C. albicans isolated from fecal specimens,
this finding would be expected. Nevertheless, a report
using a peptide nucleic acid fluorescent in situ hybridi-
zation analysis showed incidences of 7% in blood
specimens [52].
The new yeast species belonging to the C. parapsi-
losis group, C. metapsilosis and C. orthopsilosis, were
described during 2005 [23]. C. metapsilosis, was pre-
viously classified as C. parapsilosis group III and was
considered a non-pathogen [53,55]. The species was
thought to be best adapted to a non-mammalian
environment, as opposed to C. parapsilosis and
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C. orthopsilosis [23]. Additionally, the same authors
considered the possibility of the latter species to be the
evolutional ancestor of C. parapsilosis and C. orthopsi-
losis. An in vitro study compared the virulence of the
three species in human reconstituted epidermis and
oral epithelium, indicating that C. metapsilosis is less
virulent than C. parapsilosis and C. orthopsilosis [54].
Nevertheless, Kocsube´ and co-workers reported the
isolation of a C. metapsilosis from a BSI [55]. And,
recently it was reported in Spain that the prevalence of
C. metapsilosis is 1.7% and 1.4% for C. orthopsilosis, as
agents of candidemia [56]. Here we described one case
of systemic infection/colonization by C. metapsilosis
from a very critical patient. During the 4-year period of
this study, the number of BSI due to C. orthopsilosis
was one.
Final remarks
This study intended to analyze yeasts isolated from
every possible biological specimen. In the literature, we
could not find studies with a similar objective and the
majority of available studies focus on BSI. The presence
and isolation of yeasts from normally sterile sites, such
as blood and cerebrospinal fluid, is sufficient to make a
diagnosis of infection, while yeasts recovered from
wounds, urine, sputum or faeces have a reserved
etiological significance as they could be commensals
and/or yeast contaminants. The diagnosis of diseases
caused by yeasts has to be based on clinical data (fever,
skin lesions) and epidemiologic indicators (risk fac-
tors), rather than just on the isolation of the fungus
[57]. However, even if a yeast isolate is not considered
as an agent of infection at one site, its presence may be
the basis for the development of a secondary pathology.
Colonization is a factor of increased risk for many
fungal infections. Because of their opportunistic nature,
they may continue as colonizers until the host enters a
clinical state that is favourable for proliferation and
invasion of tissue [58,59].
Acknowledgements
The authors acknowledge Helena Ferreira, Maria
Trindade Marques, Henrique Jorge Marques and
Marta Mota for technical support. The authors
acknowledge the Novexem Portugal for helping in the
statistical analysis. This work was partially granted by a
financed project by Ageˆncia de Inovac¸a˜o  MCTES
(Projecto PYM).
Declaration of interest: The authors report no conflicts
of interest. The authors alone are responsible for the
content and writing of the paper.
References
1 Voss A, Hollis RJ, Pfaller MA, Wenzel RP, Doebbeling BN.
Investigation of the sequence of colonization and candidemia in
nonneutropenic patients. J Clin Microbiol 1994; 32: 975980.
2 Reagan DR, Pfaller MA, Hollis RJ, Wenzel RP. Characterization
of the sequence of colonization and nosocomial candidemia using
DNA fingerprinting and a DNA probe. J Clin Microbiol 1990; 28:
27332738.
3 Burnie JP, Odds FC, Lee W, Webster C, Williams JD. Outbreak of
systemic Candida albicans in an intensive care unit caused by cross
infection. British Med J 1985; 290: 746748.
4 Betremieux P, Chevrier S, Quindos G, et al. Use of DNA
fingerprinting and biotyping methods to study a Candida albicans
outbreak in a neonatal intensive care unit. Pediatr Infect Dis J
1994; 13: 899905.
5 Vaudry WL, Tierney AJ, Wenman WM. Investigation of a cluster
of Candida albicans in a neonatal intensive care unit. J Infect Dis
1988; 158: 13761379.
6 Hedderwick SA, Lyons MJ, Liu M, Vazquez JA, Kauffman CA.
Epidemiology of yeast colonization in the intensive care unit. Eur
J Clin Microbiol Infect Dis 2000; 19: 663670.
7 Eggimann P, Garbino J, Pittet D. Epidemiology of Candida
species in critically ill non-immunosuppressed patients. Lancet
Infect Dis 2003; 3: 685702.
8 Richardson MD. Changing patterns and trends in systemic fungal
infections. J Antimicrob Chemother 2005; 56 (Suppl. 1): i5i11.
9 Sendid B, Cotteau A, Franc¸ois N, et al. Candidaemia and
antifungal therapy in a French university hospital: Rough trends
over a decade and possible links. BMC Infect Dis 2006; 6: 8089.
10 Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a
persistent public health problem. Clin Microbiol Rev 2007; 20:
133163.
11 Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging
and uncommon medically important fungal pathogens. Clin
Microbiol Infec 2004; 10: 4866.
12 Costa-de-Oliveira S, Pina-Vaz C, Mendonc¸a D, Gonc¸alves-
Rodrigues A. A first Portuguese epidemiological survey of
fungaemia in a university hospital. Eur J Clin Microbiol Infect
Dis 2008; 24: 2330.
13 Pappas PG, Rex JH, Lee J, et al. Prospective observational study
of candidemia: epidemiology, therapy, and influences on mortality
in hospitalized adult and pediatric patients. Clin Infect Dis 2003;
37: 634643.
14 Sanglard D, Odds FC. Resistance of Candida species to antifungal
agents: molecular mechanisms and clinical consequences. Lancet
Infect Dis 2002; 2: 7385.
15 Buchner T, Fegeler W, Bernhardt H, et al. Treatment of severe
Candida infections in high-risk patients in Germany: consensus
formed by a panel of interdisciplinary investigators. Eur J Clin
Microbiol Infect Dis 2002; 21: 337352.
16 Pappas PG, Rex JH, Sobel JD, et al. Guidelines for the treatment
of candidiasis. Clin Infect Dis 2004; 38: 161189.
17 Hoppe JE, Frey P. Evaluation of six commercial tests and the
germ-tube test for presumptive identification of Candida albicans.
Eur J Clin Microbiol 1999; 18: 188191.
– 2009 ISHAM, Medical Mycology
8 Paulo et al.
D
o
w
n
lo
ad
ed
 B
y:
 [
B-
on
 C
on
so
rt
iu
m 
- 
20
07
] 
At
: 
14
:2
3 
25
 A
ug
us
t 
20
09
18 Borman AM, Linton CJ, Miles SJ, Johnson EM. Molecular
identification of pathogenic fungi. J Antimicrob Chemother 2008;
61: i7i12.
19 Guillamo´n JM, Sabate´ J, Barrio E, Cano J, Querol A. Rapid
identification of wine yeast species based on RFLP analysis of the
ribosomal ITS regions. Arch Microbiol 1998; 169: 387392.
20 Esteve-Zarzoso B, Belloch C, Uruburu F, Querol A. Identification
of yeasts by RFLP analysis of the 5.8S rRNA gene and the two
ribosomal internal transcribed spacers. Int J Syst Bacteriol 1999;
49: 329337.
21 Llanos-Frutos R, Ferna´ndez-Espinar MT, Querol A. Identifica-
tion of species of the genus Candida by analysis of the 5.8S rRNA
gene and the two ribosomal internal transcribed spacers. Anton
Leeuw Int J G 2004; 85: 175185.
22 Kurtzman CP, Robnett CJ. Identification and phylogeny of
ascomycetous yeasts from analysis of nuclear large subunit (26S)
ribosomal DNA partial sequences. Anton Leeuw Int J G 1998; 73:
331371.
23 Tavanti A, Davidson AD, Gow NAR, Maiden MCJ, Odds FC.
Candida orthopsilosis and Candida metapsilosis spp. nov. to
replace Candida parapsilosis Groups II and III. J Clin Microbiol
2005; 43: 284292.
24 Leo´n C, Ruiz-Santana S, Saavedra P, et al. EPCAN Study Group.
A bedside scoring system (‘‘Candida score’’) for early antifungal
treatment in nonneutropenic critically ill patients with Candida
colonization. Crit Care Med 2006; 34: 730737.
25 Thomas DP, Bachmann SP, Lopez-Ribot JL. Proteomics for the
analysis of the Candida albicans biofilm lifestyle. Proteomics 2006;
6: 57955804.
26 Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis
2005; 41: 521526.
27 Essman M, Larsen B. Protective effect of the selective estrogen
receptor modulator LY117018 on rat vaginal Candida albicans
colonization. Gynecol Obstet Invest 2000; 49:5761.
28 Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common
infections in diabetes: pathogenesis, management and relationship
to glycaemic control. Diabetes Metab Res Rev 2007; 23: 313.
29 Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retro-
spective development and validation of a clinical prediction rule
for nosocomial invasive candidiasis in the intensive care setting.
Eur J Clin Microbiol Infect Dis 2007; 26: 271276.
30 Fidel PL. Candida-host interactions in HIV disease: Relationships
in oropharyngeal candidiasis. Adv Dent Res 2006; 19: 8084.
31 Aw D, Silva AB, Palmer DB. Immunosenescence: emerging
challenges for an ageing population. Immunology 2007; 120:
435446.
32 Laube S. Skin infections and ageing. Ageing Res Rev 2004; 3: 69
89.
33 Brawner DL, Cutler JE. Oral Candida albcans isolates from non-
hospitalized normal carriers, immunocompetent hospitalized
patients, and immunocompromised patients with or without
acquired immunodeficiency syndrome. J Clin Microbiol 1989;
27: 13351341.
34 Kullberg BJ, Oude-Lashof AML. Epidemiology of opportunistic
invasive mycoses. Eur J Med Res 2002; 7: 183191.
35 Odds FC, Hanson MF, Davidson AD, et al. One year prospective
survey of Candida bloodstream infections in Scotland. J Med
Microbiol 2007; 56: 10661075.
36 Ellepola AN, Morrison CJ. Laboratory diagnosis of invasive
candidiasis. J Microbiol 2005; 43: 6584.
37 Horvath LL, Hospenthal DR, Murray CK, Dooley DP. Detection
of simulated candidemia by the BACTEC 9240 system with Plus
Aerobic/F and Anaerobic/F Blood Culture Bottles. J Clin Micro-
biol 2003; 41: 47144717.
38 Maaroufi Y, De Bruyne JM, Duchateau V, Georgala A, Crokaert
F. Early detection and identification of commonly encountered
Candida species from simulated blood cultures by using a real-
time PCR-based assay. J Molec Diagn 2004; 41: 32933298.
39 White PL, Barton R, Guiver M, et al. Consensus on fungal
polymerase chain reaction diagnosis? A United-Kingdom-Ireland
evaluation of polymerase chain reaction methods for detection of
systemic fungal infections. J Mol Diagn 2006; 8: 376384.
40 White TJ, Bruns T, Lee S, Taylor J. Amplification and direct
sequencing of fungal ribosomal RNA genes for phylogenetics. In
Innis MA, Gelfand Dh, Sninsky JJ, White TJ, (eds.) PCR
Protocols: a Guide to Methods and Applications. San Diego, CA:
Academic Press, 1990: 315322.
41 Trost A, Graf B, Eucker J, et al. Identification of clinically relevant
yeasts by PCR/RFLP. J Microb Meth 2003; 56: 201211.
42 Fridkin SK. The changing face of fungal infections in health care
settings. Clin Infect Dis 2005; 41: 14551460.
43 Garcı´a-Martos P, Domı´nguez I, Marin P, et al. Antifungal
susceptibility of emerging yeast pathogens. Enferm Infec Microbiol
Clin 2001; 19: 249256.
44 Ruiz-Diez B, Martinez V, Alvarez M, Rodriguez-Tudela JL,
Martinez-Suarez JV. Molecular tracking of Candida albicans in
a neonatal intensive care unit: long-term colonizations versus
catether related infections. J Clin Microbiol 1997; 35: 30323036.
45 Reef SE, Lasker BA, Butcher DS, et al. Nonperinatal nosocomial
transmission of Candida albicans in a neonatal intensive care unit:
prospective study. J Clin Microbiol 1998; 36: 12551259.
46 Waggoner-Fountain LA, Walker MW, Hollis RJ, et al. Vertical
and horizontal transmission of unique Candida species to
premature newborns Clin Infect Dis 1996; 22: 803808.
47 Rangel-Frausto MS, Houston AK, Bale MJ, Fu C, Wenzel RP. An
experimental model for study of Candida survival and transmis-
sion in human volunteers. Eur J Clin Microbiol Infect Dis 1994;
13: 590595.
48 de Llanos-Frutos R, Fernandez-Espinar MT, Querol A. A
comparison of clinical and food Saccharomyces cerevisiae isolates
on the basis of the potential virulence factors. Anton Leeuw Int J
G 2006; 90: 221231.
49 Meis JF, Lunel FM, Verweij PE, Voss A. One-year prevalence of
Candida dubliniensis in a Dutch university hospital. J Clin
Microbiol 2000; 38: 31393140.
50 Mosaid A, Sullivan D, Salkin IF, Shanley S, Coleman DC.
Differentiation of Candida dubliniensis from Candida albicans on
Staib Agar and Caffeic Acid-Ferric Citrate Agar. J Clin Microbiol
2001; 39: 323327.
51 Jabra RM, Baqui AA, Kelley JA, et al. Identification of Candida
dubliniensis in a prospective study of patients in the United States.
J Clin Microbiol 1999; 37: 321326.
52 Jabra-Rizk MA, Johnson JK, Forrest G, et al. Prevalence of
Candida dubliniensis fungemia at a large teaching hospital. Clin
Infect Dis 2005; 41: 10641067
53 Clark TA, Morgan J, Brandt M, et al. Hospital outbreak of
Candida parapsilosis bloodstream infections  Mississippi, 2001.
Proceedings of the 42nd Intersci Conf Antimicrob Agents Che-
mother, San Diego, California. 2002: M-880.
54 Ga´cser A, Scha¨fer W, Nosanchuk JS, Salomon S, Nosanchuk JD.
Virulence of Candida parapsilosis, Candida orthopsilosis, and
Candida metapsilosis in reconstituted human tissue models. Fungal
Genet Biol 2007; 44: 13361341.
– 2009 ISHAM, Medical Mycology
Yeast infection epidemiology 9
D
o
w
n
lo
ad
ed
 B
y:
 [
B-
on
 C
on
so
rt
iu
m 
- 
20
07
] 
At
: 
14
:2
3 
25
 A
ug
us
t 
20
09
55 Kocsube´ S, To´th M, Va´gvo¨lgyi C, et al. Occurrence and genetic
variability of Candida parapsilosis sensu lato in Hungary. J Med
Microbiol 2007; 56: 190195.
56 Gomez-Lopez A, Alastruey-Izquierdo A, Rodriguez D, et al.
Prevalence and susceptibility profile of Candida metapsilosis and
Candida orthopsilosis. Results from population-based surveillance
of candidemia in Spain. Antimicrob Agents Chemother 2008; 52:
15061509.
57 Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic
invasive fungal infections in immunocompromised patients with
cancer and hematopoietic stem cell transplants: an international
consensus. Clin Infect Dis 2002; 34: 714.
58 O’Donnell K. Ribosomal DNA internal transcribed spacers are
highly divergent in the phytopathogenic ascomycete Fusarium
sambucinum (Gibberella pulicaris). Curr Genet 1992; 22: 213220.
59 Agvald-O¨hman C, Klingspor L, Hjelmqvist H, Edlund C.
Invasive candidiasis in long-term patients at a multidisciplinary
intensive care unit: Candida colonization index, risk factors,
treatment and outcome. Scand J Infect Dis 2008; 40: 145153.
– 2009 ISHAM, Medical Mycology
10 Paulo et al.
D
o
w
n
lo
ad
ed
 B
y:
 [
B-
on
 C
on
so
rt
iu
m 
- 
20
07
] 
At
: 
14
:2
3 
25
 A
ug
us
t 
20
09
